Plus   Neg

NVS : Iscalimab Shows Extended Survival Of Transplanted Organs May Be Possible

Novartis' (NVS) early stage histology data in kidney transplantation suggests that its investigational compound Iscalimab maybe capable of prolonging the durability of transplanted kidneys as well as potentially improving long-term outcomes for kidney transplant patients.

The findings are to be confirmed in an ongoing phase IIb trial.

According to the data, three of five (60%) of Iscalimab-treated transplant patients have normal kidney histology at least 1 year after transplant compared to none of seven (0%) patients treated with Tacrolimus, the current standard of care.

"Extending the life of transplanted kidneys would mean fewer patients going back on dialysis or needing a second transplant - relieving pressure on waiting lists that in the US are already three-to-five years long," said Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology.

For comments and feedback contact: editorial@rttnews.com

Follow RTT